ArticleTanaffos2016
Cost Analysis of Hospitalized Patients with Chronic Obstructive Pulmonary Disease: A State-Level Cross-Sectional Study.
Article in Tanaffos, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Economic burden of chronic obstructive pulmonary disease and post-tuberculosis sequelae in low- and middle-income countries: a database compiled from a systematic review and meta-analysis.BMJ public health · 2024Article
- A prospective study on direct out-of-pocket expenses of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in a Philippine tertiary care center.BMC pulmonary medicine · 2024Article
- Article
- Hospitalization costs of COPD cases and its associated factors: an observational study at two large public tertiary hospitals in Henan Province, China.BMC geriatrics · 2023Observational
- Risk Factors for Length of Hospital Stay in Acute Exacerbation Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study.International journal of general medicine · 2022Article
- Distributional health and financial consequences of increased cigarette tax in Iran: extended cost-effectiveness analysis.Health economics review · 2021Article
- Assessment and valuation of health impacts of fine particulate matter during COVID-19 lockdown: a comprehensive study of tropical and sub tropical countries.Environmental science and pollution research international · 2021Article
- Preventing COPD Readmissions Under the Hospital Readmissions Reduction Program: How Far Have We Come?Chest · 2021Review
- Article
- Trends in Hospitalization Expenditures for Acute Exacerbations of COPD in Beijing from 2009 to 2017.International journal of chronic obstructive pulmonary disease · 2020Article
- The use of a standardized order set reduces systemic corticosteroid dose and length of stay for individuals hospitalized with acute exacerbations of COPD: a cohort study.International journal of chronic obstructive pulmonary disease · 2018Article
- The impact on thirty day readmissions for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease admitted to an observation unit versus an inpatient medical unit: A retrospective observational study.Chronic respiratory diseaseObservational
- Out-of-pocket costs associated with chronic respiratory diseases in Korean adults.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a common disease with important healthcare, social, and economic consequences. The aim of this study was to analyze the costs of hospitalizing patients with COPD. MATERIALS AND
methodsIn this state-level cross-sectional study, data from 165 COPD patients who had presented to our hospital between April 1, 2011 and March 31, 2013 were reviewed retrospectively. Patients were eligible for inclusion if they had a diagnosis of COPD [international classification of diseases-10 (ICD-10) code J44]. Costs of COPD patients were calculated by multiplying the amount of services used by the unit cost. Finally, we used multivariate regression analysis to determine predictors of hospital costs.
resultsMean (SD) age of the patients was 68.6 ± 12 years and 65.5% of them were ≥ 65. The mean (SD) and median length of stay (LOS) for patients were 8.5 ± 11.5 and five days [IQR 3; 9], respectively. All hospital cost drivers had significant relationships with LOS, and the mean cost per patient was higher in patients with hospital LOS longer than nine days. Prolonged LOS (LOS > 9 days) involved 830 bed/days. Therefore, the mean cost per each extra day of hospital stay was estimated to be US $115.80. The mean costs per patient with and without hypertension were US $1,422.5 and US $627.4, respectively (P=0.017).
conclusionHospitalization and medication costs were the two major cost drivers for patients hospitalized with COPD exacerbation. Duration of hospital stay, history of hypertension, and the number of clinical consultations other were significant predictors associated with hospital cost in patients with COPD.
Indexed as
Identifiers
27904538PMC5127618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.